drugset / Trial / NCT02302599

Mesenchymal Stem Cells to Treat Type 2 Diabetes

NCT02302599

Phase 2 Completed 103 enrolled Chinese PLA General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Umbilical cord mesenchymal stem cells indicate the therapeutic effects and safety on type 2 diabetes by characteristics of secretion and immune Immunomodulation.

Timeline

Start
2013-01
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 1.5e+06 cells/kg Intravenous